If you have worked through two or more antidepressants without finding lasting relief, your psychiatrist has probably mentioned that other options exist. In Boca Raton and across South Florida, two names tend to dominate that conversation: transcranial magnetic stimulation (TMS) and ketamine infusions. Both have accumulated genuine clinical credibility. Both are available locally. Both target treatment-resistant depression through mechanisms that bypass the standard serotonin-reuptake pathway. Yet they are fundamentally different treatments - different science, different day-to-day experiences, different safety profiles, and very different relationships with health insurance.
This guide walks through what each treatment actually involves, what the published research says about effectiveness and safety, how the costs compare in the Boca Raton market, and which type of patient tends to respond better to each approach. The goal is not to declare a winner. It is to help you and your prescribing clinician ask the right questions before committing to a multi-week treatment course that takes real time, real energy, and in many cases real money.
Why Boca Raton Patients Are Facing This Choice More Often
South Florida has become one of the more concentrated markets for innovative mental health care in the United States. Palm Beach and Broward counties have seen a significant expansion of both dedicated TMS clinics and ketamine infusion centers over the past decade, which means Boca Raton residents have access to these treatments that most of the country still lacks. That is genuinely good news for people who have been cycling through antidepressants for years, but more options also mean more decisions. A local search for depression help in Boca Raton now returns TMS providers, IV ketamine clinics, Spravato programs certified under the FDA's REMS protocol, and combinations of all three. Without a clear framework, it is easy to choose based on which website had the most convincing marketing language rather than which treatment makes the most clinical sense for your specific history.
It also matters that these two treatment categories carry very different regulatory statuses, different insurance profiles, and different out-of-pocket costs. For many Boca Raton families navigating depression on a real-world budget, those financial differences are decisive even before clinical factors enter the picture. Understanding the full picture - medical and financial - is the best starting point for this decision.
How TMS Therapy Works
Transcranial magnetic stimulation delivers brief, targeted pulses of electromagnetic energy through the scalp to specific regions of the brain. For depression, the primary target is the left dorsolateral prefrontal cortex (DLPFC) - an area that brain imaging studies have consistently shown to be underactive in people with major depressive disorder. Repeated stimulation at the right frequency and intensity over several weeks gradually normalizes activity in that circuit, which in turn influences mood-regulating regions deeper in the brain, including the limbic system and the subgenual cingulate cortex.
The word "transcranial" is important: the magnetic field passes through the skull without surgery, without anesthesia, and without electrical current running through the body. The patient sits in a reclined chair, a figure-eight shaped treatment coil is positioned precisely against the scalp, and the device delivers a series of pulses over approximately 20 to 40 minutes depending on the specific protocol in use. The experience is often described as a tapping or clicking sensation on the scalp. Standard TMS protocols involve approximately 36 sessions delivered five days a week over six to seven weeks. Newer accelerated protocols, including what is called Stanford Neuromodulation Therapy, compress the same total stimulation into a much shorter period - sometimes as few as five days - though not all clinics offer these advanced schedules. Ask any provider you consult whether they offer only standard protocols or whether accelerated options are available for your situation.
Regulatory standing matters significantly when insurance coverage is part of your decision. The FDA cleared TMS for major depressive disorder in 2008, making it one of the longer-tenured non-pharmacological depression treatments on the market. Subsequent clearances followed for obsessive-compulsive disorder in 2018, smoking cessation in 2020, and adjunctive treatment of anxious depression - defined as depression accompanied by significant anxiety symptoms - in 2021. This regulatory history gives TMS a durability of evidence that supports insurance coverage arguments in ways that newer or off-label treatments simply cannot match.
How Ketamine Treatment Works
Ketamine is chemically and mechanistically unlike any antidepressant in standard clinical use. It is an NMDA receptor antagonist - it blocks a specific receptor in the brain's glutamate signaling system rather than targeting serotonin, dopamine, or norepinephrine. This different mechanism appears to trigger a rapid cascade of synaptic changes, essentially promoting neuroplasticity in circuits that have become rigid and dysfunctional under the weight of chronic or treatment-resistant depression. The antidepressant effect can appear within hours of a single infusion, which is one of ketamine's most remarkable and clinically significant properties - a speed that no standard oral antidepressant approaches.
There are two distinct ways to receive ketamine for psychiatric purposes, and this distinction trips up a significant number of patients when they start researching their options. The first is intravenous (IV) ketamine administered by an anesthesiologist or psychiatrist at a certified ketamine infusion clinic. IV ketamine for depression is off-label use - meaning ketamine holds FDA approval as a general anesthetic and for certain pain indications, not specifically for the treatment of depression. Each infusion typically runs 40 minutes to an hour; most induction protocols involve six infusions delivered over two to three weeks. During the infusion, patients experience dissociative effects - a dreamlike, perceptually altered state that feels detached from normal consciousness. These effects resolve within roughly one hour of the infusion ending, but patients cannot drive and must arrange transportation for every appointment.
The second form is esketamine, sold under the brand name Spravato, which is a nasal spray derived from one molecular form of ketamine. Spravato received FDA approval in 2019 specifically for treatment-resistant depression in adults who have failed at least two antidepressant medications, and a separate FDA approval in 2020 for major depressive disorder with acute suicidal ideation or behavior. Because it is FDA-approved for psychiatric use rather than off-label, Spravato occupies a better regulatory position than IV ketamine for insurance purposes. It is administered exclusively in certified healthcare settings under a Risk Evaluation and Mitigation Strategy (REMS) program - patients must remain at the clinic for at least two hours after each dose to be monitored for dissociation, blood pressure changes, and sedation. The standard induction schedule is twice weekly for four weeks, then weekly for a month, then every one to two weeks as a maintenance dose determined by the treating physician.
What Conditions Each Treatment Addresses
TMS and ketamine share a primary use case - treatment-resistant depression - but the conditions they are cleared or approved to treat diverge meaningfully beyond that overlap, and those differences matter for determining which treatment path makes sense for a given patient.
TMS has the broader FDA-cleared indication list. It is an established option for major depressive disorder generally - not only treatment-resistant cases - meaning patients who have failed one or two antidepressants can often qualify for TMS coverage without meeting the more stringent "treatment-resistant" threshold. Beyond depression, TMS holds clearances for obsessive-compulsive disorder, the specific subtype of anxious depression, and smoking cessation. Ongoing research is examining TMS for PTSD, ADHD, chronic pain, and other conditions, but those remain investigational indications at most clinics rather than standard practice.
Spravato's FDA approvals are specifically for treatment-resistant depression (failure of at least two adequate antidepressant trials of adequate dose and duration) and for major depressive disorder in adults with active suicidal ideation accompanied by intent or behavior. The rapid-onset property that makes ketamine clinically exciting is particularly relevant for that second indication - few other non-hospitalization interventions can meaningfully reduce suicidal ideation within hours. IV ketamine is used off-label for similar presentations but without the same regulatory framework or required monitoring structure.
Practically speaking: if your primary diagnosis is major depression and you have failed at least two antidepressant medications, you may be a candidate for either treatment. If your presentation includes significant OCD symptoms or anxious depression as a primary feature, TMS has specific clearances for those diagnoses. If you are in acute psychiatric crisis with active suicidal ideation requiring rapid stabilization, the speed of ketamine's effect may make it the more pressing short-term intervention, with TMS potentially following as a consolidation strategy once the immediate crisis has passed.
What a Full Treatment Course Actually Looks Like
The logistical realities of these two treatments are quite different, and for working Boca Raton professionals, parents managing school schedules, or anyone with a structured daily routine, the practical demands of each course often shape the decision as much as clinical factors do.
A standard TMS course runs five days a week for six to seven weeks - approximately 36 sessions in total. Each session is 20 to 40 minutes in the chair plus brief check-in time, so most patients plan for roughly an hour per visit including parking and check-in. After each session, patients are fully free to drive, return to work, handle childcare, or go about their day normally. There are no lingering cognitive effects, no sedation, and no requirement for supervision afterward. Many patients in Boca Raton schedule their daily TMS appointments first thing in the morning before heading to offices in Boca or commuting south toward Fort Lauderdale or Miami. The five-days-a-week cadence does require real schedule planning across six weeks, and it is worth asking any clinic about their policy for missed sessions, makeup appointments, and flexibility around travel.
An IV ketamine induction course involves six infusions delivered over roughly two to three weeks - a much shorter initial commitment in terms of calendar time. Each infusion runs 40 to 60 minutes, but the requirement to remain in the clinic for post-infusion observation and then arrange transportation home means each appointment blocks three to four hours from your day. You cannot drive after a ketamine infusion, period. That means either a family member, rideshare, or taxi is required for every single appointment. After the induction series, most patients need maintenance infusions on a schedule of roughly once a month to sustain the antidepressant effect, which means the ketamine commitment extends indefinitely rather than concluding after a defined course. Spravato follows a more structured decreasing-frequency schedule built into its approval label, but the monitoring requirement and transportation need remain consistent throughout.
Both treatments are entirely outpatient. Neither requires hospitalization. Neither causes the kind of physical recovery period that surgery or ECT would demand. Those surface similarities can obscure how differently the day-to-day experience of each course feels to a patient navigating it over weeks and months.
Side Effects and Safety: A Realistic Comparison
Neither TMS nor ketamine is free of side effects, but their risk profiles look very different from each other, and understanding those differences is essential for choosing well.
TMS Side Effects
The most common side effect of TMS is discomfort or mild pain at the scalp site where the treatment coil contacts the head, particularly during the first one to two weeks of treatment as patients acclimate to the sensation. Headache is also frequently reported after early sessions. Both effects tend to diminish significantly as treatment progresses, and taking an over-the-counter analgesic 30 to 60 minutes before a session can help manage discomfort during the initial adjustment period. Some patients experience slight facial muscle twitching during the pulse sequences; this is a normal response to the magnetic field and does not indicate anything is wrong.
Critically, TMS produces no systemic side effects because it has no pharmacological component - nothing enters the bloodstream. It does not cause weight gain, sexual dysfunction, gastrointestinal distress, dry mouth, or the cognitive blunting that drives many patients away from antidepressant medications in the first place. This clean systemic profile is a meaningful advantage for patients who have had difficult side effect experiences with multiple medication trials.
The most serious risk associated with TMS is seizure induction. Published safety data put this risk at approximately 1 in 30,000 sessions - well under 0.1 percent of patients. Most TMS clinics screen patients carefully for personal or family seizure history and other risk factors before starting treatment, which keeps this risk minimal for appropriately selected patients. TMS does not carry the cognitive side effects historically associated with electroconvulsive therapy. It is compatible with most psychiatric medications, and patients typically continue their current medications throughout the TMS course. Certain metal implants near the head or neck are contraindications; discuss your full medical and implant history with any TMS provider before treatment begins.
Ketamine Side Effects
The dissociative experience during a ketamine infusion - the dreamlike, floaty, perceptually altered state - is not a side effect in the traditional sense but rather a direct consequence of how the drug acts on the brain. The intensity varies between patients and even between sessions. Most patients find it manageable or neutrally interesting; some find it uncomfortable or anxiety-provoking. Clinics experienced with ketamine infusions know how to support patients through difficult dissociative reactions, and the environment in which the infusion takes place - lighting, music, the presence of staff - influences the experience significantly.
Nausea is common during and immediately after infusion, and some clinics administer anti-nausea medication prophylactically. Blood pressure and heart rate typically rise during the infusion, which is why patients with poorly controlled hypertension or certain cardiovascular conditions require careful medical evaluation before starting. Dizziness and short-term memory impairment are reported after individual sessions but resolve within hours for the vast majority of patients.
There is no evidence of lasting cognitive impairment from a standard clinical course of IV ketamine or Spravato administered under medical supervision for depression at appropriate intervals. The serious bladder damage (ketamine cystopathy) and cognitive problems associated with ketamine in some reports come from high-frequency or high-dose recreational use over extended periods - a very different exposure pattern from clinical treatment. However, this context is one reason why ongoing medical oversight is non-negotiable when ketamine is used therapeutically, and why self-administered or informally obtained ketamine for depression is genuinely dangerous.
Ketamine is not appropriate for patients with active psychotic disorders, active substance use disorder (particularly a history of dissociative or hallucinogenic drug misuse), uncontrolled hypertension, or certain thyroid conditions. A thorough medical and psychiatric evaluation by a qualified physician before starting any ketamine program is not optional - it is a core component of safe treatment.
Cost and Insurance Coverage in Boca Raton
This is where the two treatments diverge most sharply for many patients, and it deserves clear, direct discussion without the euphemisms that often appear in clinic marketing materials.
TMS Cost and Insurance
TMS has a well-established insurance coverage pathway that is one of its most significant advantages over ketamine for the majority of patients. Medicare covers TMS therapy for major depressive disorder when patients have not responded adequately to antidepressant medication - the specific criteria regarding how many prior medication trials are required varies by Medicare Administrative Contractor and has been updated over time, so verify current requirements at medicare.gov or directly with a TMS provider who is familiar with Florida MAC requirements. Most major commercial insurers whose plans are commonly used by Boca Raton residents - including Blue Cross Blue Shield of Florida, Aetna, Cigna, UnitedHealthcare, and Humana - cover TMS for major depressive disorder under broadly similar criteria, generally requiring documentation of two to four failed antidepressant trials of adequate dose and duration, combined with a formal diagnosis of MDD. Prior authorization is almost universally required, and a well-run TMS clinic will help you gather the documentation needed for that process.
Out-of-pocket costs for patients whose insurance covers TMS depend on their specific plan's deductible, coinsurance, and out-of-pocket maximum - not on a published TMS price list. Contact any clinic you are considering and ask them directly what the self-pay price for a complete course is, and whether payment plans are available. Do not rely on figures quoted on websites as current, as pricing varies and changes.
Ketamine Cost and Insurance
IV ketamine infusions for depression are almost universally not covered by health insurance because the psychiatric use is off-label. Patients pay entirely out of pocket. Per-infusion costs at South Florida clinics vary by provider and change over time; verify current pricing directly with any clinic you consult rather than relying on any figure cited online or in this article. A standard six-infusion induction course typically runs several thousand dollars in total, and the need for ongoing maintenance infusions means the cumulative cost continues to grow over months and years. For many Boca Raton patients, this financial reality rules out IV ketamine as a sustainable long-term approach.
Spravato occupies meaningfully better insurance ground because of its FDA approval status for treatment-resistant depression. Many commercial insurance plans do cover Spravato for patients who meet the clinical criteria, and the manufacturer, Janssen Pharmaceuticals, maintains a patient assistance and co-pay support program. Even with coverage, patient cost-sharing can be substantial. The Spravato prescribing information, your clinic's financial counselor, and direct contact with your insurance company are the most current and reliable sources of information on what your specific plan will actually pay. Do not assume coverage based on the FDA approval alone - prior authorization is required, and plans vary considerably in how strictly they apply the treatment-resistant criteria.
For a significant portion of people in Boca Raton who are making this decision, the insurance asymmetry between TMS and ketamine is determinative. If cost management is a priority and you meet standard TMS insurance criteria, TMS may be the only realistic path to a full, uninterrupted treatment course without placing serious financial strain on your household.
Who Tends to Be a Better Candidate for TMS
TMS is frequently the more appropriate first choice when one or more of the following applies to you:
- Insurance coverage is a priority and you can document two or more failed antidepressant trials in the current depressive episode.
- You need to maintain your full daily routine throughout treatment - working, driving, caring for children, or managing other obligations - without any impairment on treatment days.
- Your presentation includes obsessive-compulsive disorder, the anxious depression subtype, or a smoking cessation goal alongside depression, as TMS holds specific FDA clearances for each of those indications.
- You have a personal or family history of substance use disorder, particularly involving dissociative substances, making ketamine a less suitable option from a clinical risk standpoint.
- Your depression is moderate to severe but not an acute psychiatric emergency requiring a response measured in hours rather than weeks.
- You have previously used ketamine or Spravato without sustaining remission and are now looking for a treatment with a different mechanism and potentially more durable effects.
- You have a strong preference for a treatment with no systemic pharmacological effects and no post-session impairment or monitoring requirement.
Who Tends to Be a Better Candidate for Ketamine or Esketamine
Ketamine or Spravato tends to be the more pressing clinical need when:
- Speed of response is a genuine urgency - for example, when severe suicidal ideation requires rapid stabilization that cannot practically wait through six to seven weeks of daily TMS sessions.
- Your depression is formally classified as treatment-resistant (two or more failed antidepressant trials) and your psychiatrist has reason to believe the glutamatergic mechanism of ketamine is particularly appropriate for your neurobiological profile.
- You have already completed a properly administered TMS course - adequate sessions, correct coil placement, appropriate pulse parameters - without achieving adequate remission and want to pursue a mechanistically different approach.
- A shorter initial calendar commitment is medically or practically necessary, since a six-infusion ketamine induction spanning two to three weeks is a shorter acute course than six to seven weeks of TMS.
- You can reliably arrange transportation for every infusion day and the out-of-pocket financial cost is workable for your situation, either because of Spravato insurance coverage or personal resources.
- Your diagnosis specifically includes major depressive disorder with acute suicidal ideation, which is an FDA-approved indication for Spravato that does not have a comparable TMS clearance.
Can TMS and Ketamine Be Used Together?
This question comes up with increasing frequency as both treatments become more mainstream, and the honest answer is: sometimes, sequentially, under careful clinical coordination - not simultaneously in an uncoordinated way.
Some clinicians use ketamine as what they describe as a neurological "primer" - leveraging its rapid NMDA-mediated neuroplasticity effect to increase synaptic responsiveness - and then follow with TMS to consolidate and extend the response through targeted electromagnetic stimulation of the same prefrontal circuits. There is biologically coherent reasoning behind this approach: ketamine's rapid glutamate-mediated effect may make the brain's neural circuits more receptive to the repeated stimulation that TMS provides, potentially enhancing TMS outcomes in patients who might not respond to TMS alone. Early research has explored this sequential approach and reported promising findings, though the evidence base is not yet large enough to make it a universally recommended standard protocol.
Running both treatments simultaneously - active ketamine infusions during the same weeks as a TMS course - is less common and requires careful coordination. Neither treatment pharmacologically contraindicated the other in a clear-cut way, but the dissociative cognitive state that follows a ketamine infusion is not ideal for receiving a TMS session that same day, and managing the monitoring requirements, documentation, and clinical judgment for two concurrent protocols in the same patient demands an experienced team. If you are interested in a combined approach, the most important step is finding a clinic or clinician group that has genuine experience with both treatments and can coordinate your care thoughtfully, rather than having two separate providers operating in isolation from each other.
Choosing a Provider in Boca Raton
Whether you ultimately pursue TMS, ketamine, or a thoughtful sequence of both, the quality of the clinical team administering your treatment shapes your experience and your outcome in ways that marketing materials rarely capture.
For TMS specifically, look for a clinic where board-certified psychiatrists conduct thorough intake evaluations before treatment begins. TMS is a medical procedure requiring a psychiatric diagnosis, a detailed treatment history, and a clinical plan - not a wellness service you book online and start the next morning. The initial assessment should include a review of your full psychiatric history, all medications tried and their outcomes, documentation of prior treatment trials for insurance authorization purposes, and a frank discussion of what response and remission look like in practice. A facility that offers a brief telephone screen and immediately schedules your first session without a proper evaluation should raise real questions about the clinical rigor of their program.
For ketamine, physician oversight throughout every infusion is non-negotiable from a safety standpoint. Confirm that the clinic has appropriate emergency equipment accessible and that a qualified physician is present and attentive - not managing another patient in another room - during infusions. Spravato must be administered under a REMS-certified program; any legitimate Spravato provider is required by FDA to maintain that certification and the monitoring protocols it mandates.
In Boca Raton, proximity matters practically because of the treatment frequency involved in TMS. A clinic you will visit 36 times needs to be accessible enough that the round trip does not itself become a source of stress or a barrier to completing your full course. Ask about appointment scheduling flexibility, what the policy is for missed sessions, and how they handle breaks in treatment due to travel or illness. Completion of the full prescribed course is strongly associated with better outcomes in TMS - dropping out at session 20 because the logistics became unworkable is a clinical outcome problem, not just a scheduling inconvenience.
Frequently Asked Questions
Is TMS or ketamine more effective for depression?
Response rates are broadly similar for both treatments - published data generally put real-world response rates in the range of 50 to 60 percent for each, with remission rates somewhat lower. The key practical difference is speed: ketamine often produces noticeable antidepressant effects within hours or days of the first infusion, while TMS effects build gradually and typically become most apparent after the third or fourth week of daily sessions. Neither treatment works for everyone, and individual results depend heavily on the specific depression diagnosis, prior treatment history, medication status during treatment, and factors that are not fully predictable in advance. Consult with a board-certified psychiatrist familiar with both options for guidance specific to your clinical profile.
Does insurance cover ketamine infusions for depression in Florida?
Standard IV ketamine infusions for depression are off-label and are almost universally not covered by health insurance, including Medicare and Florida Medicaid. Patients pay entirely out of pocket. Spravato (esketamine nasal spray), which carries FDA approval for treatment-resistant depression, has meaningfully better insurance coverage, though prior authorization is required and coverage varies by plan. Contact your specific insurance plan directly and have the ketamine or Spravato provider walk you through their experience with your payer before you assume any coverage exists or estimate your out-of-pocket costs.
Can I drive myself after a TMS session?
Yes, without restriction. TMS causes no sedation, no dissociation, and no cognitive impairment that would affect driving or any other daily activity. The vast majority of TMS patients drive themselves to every session, go straight to work or home afterward, and experience no treatment-day functional limitations at all. This is one of the most practically significant advantages TMS holds over ketamine infusions, where patients are prohibited from driving on infusion days due to dissociative effects and must arrange transportation for every appointment throughout the entire treatment course.
How long do the results of TMS last compared to ketamine?
TMS response tends to be durable for many patients. Published data and real-world clinical experience suggest that a meaningful proportion of TMS responders maintain improvement for a year or longer, and some patients go several years before needing a booster course. Ketamine's antidepressant effect, while remarkable in its speed, is often shorter-lived - effects from an induction course may last weeks to a few months before fading, which is why most clinical protocols build in ongoing maintenance infusions to sustain the response. This difference in durability does not make one treatment categorically better than the other, but it does affect the long-term time and financial commitment each treatment requires.
Can TMS and ketamine be used together?
Yes, sequentially - and with increasing interest from clinicians who work with both. The most studied approach uses ketamine first to rapidly promote neuroplasticity, then follows with TMS to consolidate and extend the response through targeted circuit stimulation. This sequence has a logical biological rationale and early supporting research, though it is not yet a universally standardized protocol. If you are interested in this approach, seek out a clinic or coordinated clinical team that has actual experience managing patients through both treatments - sequential or combined care requires more clinical coordination than either treatment alone.
Is TMS safe if I have a metal implant?
It depends on what the implant is and where it is located. Metal implants near the head or neck - such as cochlear implants, aneurysm clips, metal plates in the skull, or certain types of implanted stimulators - can be contraindications for TMS because of the strong magnetic fields the treatment generates. Metal implants located far from the treatment site - dental fillings, orthopedic hardware in the spine or limbs, most types of body jewelry - are generally not a concern. Cardiac pacemakers are typically not a disqualifying factor for TMS because the magnetic field does not reach the chest, but the clinic will need to review your specific device. Bring a complete list of all implants, surgical hardware, and prior neurosurgical procedures to your initial consultation so the clinical team can conduct a thorough safety review before scheduling your first session.
If you are trying to decide between TMS therapy and ketamine treatment in Boca Raton - or wondering whether your specific history, insurance situation, and clinical profile point more clearly toward one approach - the team at our clinic is glad to help you think it through. Reach out through our contact page to request a consultation with one of our providers.